In Silico, founded in 2014 and headquartered in Cambridge, Massachusetts, raised $110 million in a Series E funding round in January 2025, bringing total funding to $510 million from investors including eBridge Ventures and Deerfield. The platform provides AI-enabled bioinformatics solutions for drug discovery, biomarker development, and aging research. Its PHARMA.AI product suite, including PandaOmics, Chemistry42, and InClinico, accelerates therapeutic development and clinical research. With strong funding and AI capabilities, In Silico is positioned to advance genomics and life sciences innovation globally.